Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide and remains a major cause of cancer-related morbidity and mortality despite advances in screening, diagnosis, and treatment. The identification of reliable biomarkers for early detection, disease monitoring, and prognostic assessment is essential for improving clinical outcomes. Fetuin-A, also known as alpha-2-HS-glycoprotein (AHSG), is a multifunctional liver-derived glycoprotein involved in diverse biological processes, including insulin signaling, inflammation, calcium metabolism, cellular adhesion, and tumor progression. Emerging evidence suggests that Fetuin-A plays a significant role in colorectal carcinogenesis through its involvement in metabolic dysregulation, chronic inflammation, extracellular vesicle-mediated signaling, epithelial–mesenchymal transition, and tumor microenvironment remodeling. Elevated Fetuin-A expression has been associated with enhanced tumor cell proliferation, migration, invasion, angiogenesis, and metastatic potential. Furthermore, Fetuin-A may contribute to immune evasion and resistance to anticancer therapies by activating multiple oncogenic pathways and facilitating communication between cancer cells and stromal components. Several clinical studies have reported altered circulating Fetuin-A levels in patients with colorectal cancer, highlighting its potential utility as a non-invasive biomarker for disease detection and progression assessment. In addition, the close relationship between Fetuin-A, obesity, insulin resistance, and metabolic syndrome provides further insight into the mechanistic links between metabolic disorders and colorectal tumorigenesis. This review comprehensively summarizes the current knowledge regarding the molecular mechanisms through which Fetuin-A influences colorectal cancer development and progression, evaluates its clinical relevance as a diagnostic and prognostic biomarker, and discusses its potential as a therapeutic target. Collectively, available evidence supports the growing importance of Fetuin-A as a promising biomarker and molecular mediator in colorectal cancer pathogenesis and clinical management.
No takes yet. Share an insight, caveat, or question.
Muner et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: